Fyarro
Fyarro ingredients
| Active ingredient | Strength |
|---|---|
| Sirolimus | 5 mg/mL |
What Fyarro is used for
The FDA lists the approved uses on the official label (below). In the EU, sirolimus is approved as Hyftor for:
Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Fyarro
- Generic name
- Sirolimus
- Made by
- Aadi Bioscience, Inc.
- Forms
- Injection, Powder, Lyophilized, For Suspension
- Given
- Intravenous
- Drug class
- Kinase Inhibitor, mTOR Inhibitor Immunosuppressant
- FDA approval
- New drug application (NDA) NDA213312
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Sirolimus)
In India
- Sirolimus: 15 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fyarro?
Fyarro (Sirolimus) is a cancer medicine made by Aadi Bioscience, Inc., approved by the US FDA.
What are the ingredients of Fyarro?
Fyarro contains Sirolimus (5 mg/mL).
Is Fyarro approved in Europe?
The same active substance is approved in the EU as Hyftor, Rapamune.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA